Drugs by condition
Drugs approved for bladder and urothelial cancer
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
16
Still marketed, NDA or BLA
Drug classes
7
Novel drugs
10
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for bladder and urothelial cancer.
- Axycis (Cisplatin) · Avyxa Holdings Oct 29, 2026
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
- Inlexzo (Gemcitabine Hydrochloride) · Janssen Biotech Breakthrough therapyPriority reviewSep 9, 2025
- Zusduri (Mitomycin) · Urogen Pharma Jun 12, 2025
- Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers Squibb Accelerated approvalDec 27, 2024
All approved drugs for bladder and urothelial cancer, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 6 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Programmed Death Receptor-1 Blocking Antibody (4)
- Tecentriq Atezolizumab · Genentech INC · 2016
- Opdivo Nivolumab · Bristol Myers Squibb · 2014
- Keytruda Pembrolizumab · Merck Sharp Dohme · 2014
- Tecentriq Hybreza Atezolizumab and Hyaluronidase-Tqjs · Genentech INC · 2024
Endoglycosidase (2)
- Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
- Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024
Programmed Death Ligand-1 Blocker (2)
Platinum-based Drug (2)
- Platinol-Aq Cisplatin · Hq Spclt Pharma · 1978
- Axycis Cisplatin · Avyxa Holdings · 2026
Kinase Inhibitor (1)
- Balversa Erdafitinib · Janssen Biotech · 2019
Nucleoside Metabolic Inhibitor (1)
- Inlexzo Gemcitabine Hydrochloride · Janssen Biotech · 2025
Class not listed in FDA's data (4)
- Anktiva Nogapendekin Alfa Inbakicept-Pmln · Altor Bioscience, LLC, An Indirect Wholly-Owned Su · 2024
- Padcev Enfortumab Vedotin-Ejfv · Astellas · 2019
- Zusduri Mitomycin · Urogen Pharma · 2025
- Cysview Kit Hexaminolevulinate Hydrochloride · Photocure Asa · 2010
Drugs in development for bladder and urothelial cancer
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- BudigalimabABBV-181Phase 36 trials
AbbVie · Hepatocellular Carcinoma, Non Small Cell Lung Carcinoma, c-MET
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
- TAR-200JNJ-17000139, Gemcitabine-Releasing Intravesical SystemPhase 35 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer
- Cretostimogene GrenadenorepvecCG0070Phase 34 trials
CG Oncology, Inc. · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- LivmoniplimabABBV-151Phase 34 trials
AbbVie · Hepatocellular Carcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer
- SHR-1501Phase 34 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Papillary-Only Non-muscle-invasive Bladder Cancer, Patients With Advanced or Metastatic Malignant Tumors, NMIBC
- BrigimadlinBI 907828Phase 33 trials
Boehringer Ingelheim · Solid Tumours, Pancreatic Neoplasms, Solid Tumors
- IO102-IO103Phase 33 trials
IO Biotech · Metastatic Melanoma, Unresectable Melanoma, Melanoma
- TARA-002Phase 33 trials
Protara Therapeutics · Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
More on bladder and urothelial cancer: recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.